BioCentury
ARTICLE | Clinical News

Biopharma companies, academics, governments racing to develop medical countermeasures against novel coronavirus

January 23, 2020 10:04 PM UTC
Updated on Mar 25, 2020 at 11:57 PM UTC

The rapid sharing of the genetic sequence of the 2019 novel coronavirus (2019-nCoV), first identified in Wuhan, China, has sparked an extraordinary response from biopharma companies, academic researchers and governments.

At least seven initiatives to develop protective vaccines have been announced and at least three separate programs are under way to develop mAbs as potential therapeutics. ...